{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:08:30Z","timestamp":1789981710485,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00665-3","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:57:58Z","timestamp":1789981078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Technology profiles in FDA-approved new molecular entities, 2013\u20132024: a latent class analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Soon Kyu","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"5","key":"665_CR1","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","volume":"64","author":"DG Brown","year":"2021","unstructured":"Brown DG, Wobst HJ. A decade of FDA-approved drugs (2010\u20132019): trends and future directions. J Med Chem. 2021;64(5):2312\u201338. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01516.","journal-title":"J Med Chem"},{"issue":"3","key":"665_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/clpt.2013.115","volume":"94","author":"AS Kesselheim","year":"2013","unstructured":"Kesselheim AS, Wang B, Avorn J. Defining innovativeness in drug development: a systematic review. Clin Pharmacol Ther. 2013;94(3):336\u201348. https:\/\/doi.org\/10.1038\/clpt.2013.115.","journal-title":"Clin Pharmacol Ther"},{"key":"665_CR3","doi-asserted-by":"publisher","first-page":"h4633","DOI":"10.1136\/bmj.h4633","volume":"351","author":"AS Kesselheim","year":"2015","unstructured":"Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987\u20132014: cohort study. BMJ. 2015;351:h4633. https:\/\/doi.org\/10.1136\/bmj.h4633.","journal-title":"BMJ"},{"issue":"8","key":"665_CR4","doi-asserted-by":"publisher","first-page":"e222685","DOI":"10.1001\/jamahealthforum.2022.2685","volume":"3","author":"KN Vokinger","year":"2022","unstructured":"Vokinger KN, Kesselheim AS, Glaus CEG, Hwang TJ. Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe from 2007 to 2021. JAMA Health Forum. 2022;3(8):e222685. https:\/\/doi.org\/10.1001\/jamahealthforum.2022.2685.","journal-title":"JAMA Health Forum"},{"issue":"2","key":"665_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/cpt.3110","volume":"115","author":"L Osipenko","year":"2024","unstructured":"Osipenko L, Potey P, Perez B, Angelov F, Parvanova I, Ul-Hasan S, Mossialos E. The origin of first-in-class drugs: innovation versus clinical benefit. Clin Pharmacol Ther. 2024;115(2):342\u20138. https:\/\/doi.org\/10.1002\/cpt.3110.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"665_CR6","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/pharmaceutics15071794","volume":"15","author":"R Okuyama","year":"2023","unstructured":"Okuyama R. Chronological analysis of first-in-class drugs approved from 2011 to 2022: their technological trend and origin. Pharmaceutics. 2023;15(7):1794. https:\/\/doi.org\/10.3390\/pharmaceutics15071794.","journal-title":"Pharmaceutics"},{"issue":"7","key":"665_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.drudis.2014.11.001","volume":"20","author":"MS Kinch","year":"2015","unstructured":"Kinch MS, Hoyer D, Patridge E, Plummer M. Target selection for FDA-approved medicines. Drug Discov Today. 2015;20(7):784\u20139. https:\/\/doi.org\/10.1016\/j.drudis.2014.11.001.","journal-title":"Drug Discov Today"},{"issue":"2","key":"665_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/d41573-024-00001-x","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. 2023 FDA approvals. Nat Rev Drug Discov. 2024;23(2):88\u201395. https:\/\/doi.org\/10.1038\/d41573-024-00001-x.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"665_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2307\/2393549","volume":"35","author":"RM Henderson","year":"1990","unstructured":"Henderson RM, Clark KB. Architectural innovation: the reconfiguration of existing product technologies and the failure of established firms. Adm Sci Q. 1990;35(1):9\u201330. https:\/\/doi.org\/10.2307\/2393549.","journal-title":"Adm Sci Q"},{"key":"665_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1017\/CBO9780511499531.004","volume-title":"Applied latent class analysis","author":"JK Vermunt","year":"2002","unstructured":"Vermunt JK, Magidson J. Latent class cluster analysis. In: Hagenaars JA, McCutcheon AL, editors. Applied latent class analysis. Cambridge: Cambridge University Press; 2002. pp. 89\u2013106."},{"issue":"4","key":"665_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10705510701575396","volume":"14","author":"KL Nylund","year":"2007","unstructured":"Nylund KL, Asparouhov T, Muth\u00e9n BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535\u201369. https:\/\/doi.org\/10.1080\/10705510701575396.","journal-title":"Struct Equ Model"},{"key":"665_CR12","volume-title":"Latent class and latent transition analysis: with applications in the social, behavioral, and health sciences","author":"LM Collins","year":"2010","unstructured":"Collins LM, Lanza ST. Latent class and latent transition analysis: with applications in the social, behavioral, and health sciences. Hoboken: Wiley; 2010."},{"issue":"8","key":"665_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1377\/hlthaff.2012.0541","volume":"32","author":"M Lanthier","year":"2013","unstructured":"Lanthier M, Miller KL, Nardinelli C, Woodcock J. An improved approach to measuring drug innovation. Health Aff (Millwood). 2013;32(8):1433\u20139. https:\/\/doi.org\/10.1377\/hlthaff.2012.0541.","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"665_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2019.20288","volume":"323","author":"JJ Darrow","year":"2020","unstructured":"Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983\u20132018. JAMA. 2020;323(2):164\u201376. https:\/\/doi.org\/10.1001\/jama.2019.20288.","journal-title":"JAMA"},{"issue":"7","key":"665_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507\u201319. https:\/\/doi.org\/10.1038\/nrd3480.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"665_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrd4336","volume":"13","author":"J Eder","year":"2014","unstructured":"Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov. 2014;13(8):577\u201387. https:\/\/doi.org\/10.1038\/nrd4336.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"665_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","volume":"16","author":"JG Moffat","year":"2017","unstructured":"Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat Rev Drug Discov. 2017;16(8):531\u201343. https:\/\/doi.org\/10.1038\/nrd.2017.111.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"665_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","volume":"21","author":"F Vincent","year":"2022","unstructured":"Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022;21(12):899\u2013914. https:\/\/doi.org\/10.1038\/s41573-022-00472-w.","journal-title":"Nat Rev Drug Discov"},{"key":"665_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16:19\u201334. https:\/\/doi.org\/10.1038\/nrd.2016.230.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"665_CR20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nrd2199","volume":"5","author":"JP Overington","year":"2006","unstructured":"Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993\u20136. https:\/\/doi.org\/10.1038\/nrd2199.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"665_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s11192-020-03778-x","volume":"126","author":"I Stiller","year":"2021","unstructured":"Stiller I, van Witteloostuijn A, Cambr\u00e9 B. Do current radical innovation measures actually measure radical drug innovation? Scientometrics. 2021;126(2):1049\u201378. https:\/\/doi.org\/10.1007\/s11192-020-03778-x.","journal-title":"Scientometrics"},{"key":"665_CR22","doi-asserted-by":"publisher","first-page":"e2400087","DOI":"10.1200\/CCI.24.00087","volume":"8","author":"JG Ronquillo","year":"2024","unstructured":"Ronquillo JG, South B, Naik P, Singh R, De Jesus M, Watt SJ, Habtezion A. Informatics and artificial intelligence-guided assessment of the regulatory and translational research landscape of first-in-class oncology drugs in the United States, 2018\u20132022. JCO Clin Cancer Inf. 2024;8:e2400087. https:\/\/doi.org\/10.1200\/CCI.24.00087.","journal-title":"JCO Clin Cancer Inf"},{"issue":"11","key":"665_CR23","doi-asserted-by":"publisher","first-page":"8519","DOI":"10.1021\/acs.jmedchem.4c00568","volume":"67","author":"KA Iyer","year":"2024","unstructured":"Iyer KA, Ivanov J, Tenchov R, Ralhan K. Emerging targets and therapeutics in immuno-oncology: insights from landscape analysis. J Med Chem. 2024;67(11):8519\u201344. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00568.","journal-title":"J Med Chem"},{"issue":"35","key":"665_CR24","doi-asserted-by":"publisher","first-page":"10294","DOI":"10.1002\/anie.201611914","volume":"56","author":"E Valeur","year":"2017","unstructured":"Valeur E, Gu\u00e9ret SM, Adihou H, Gopalakrishnan R, Lemurell M, Waldmann H, Grossmann TN, Plowright AT. New modalities for challenging targets in drug discovery. Angew Chem Int Ed. 2017;56(35):10294\u2013323. https:\/\/doi.org\/10.1002\/anie.201611914.","journal-title":"Angew Chem Int Ed"},{"key":"665_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pharmtox-061724-080811","volume":"65","author":"P McGonigle","year":"2025","unstructured":"McGonigle P. How biologics have changed the drug discovery landscape. Annu Rev Pharmacol Toxicol. 2025;65:29\u201346. https:\/\/doi.org\/10.1146\/annurev-pharmtox-061724-080811.","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00665-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:57:59Z","timestamp":1789981079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00665-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00665-3","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"83"}}